Using examples of drugs and companies, Dr Andreas Persidis gives tips on how to establish a systematic drug repositioning programme. Online article in the Managing Intellectual Property website. In the absence of productive internal R&D sufficient to support growth, current pharmaceutical IP strategies focus on acquiring smaller biotechs with promising assets to bolster larger pharma’s … Read More
Guest Commentary in Drug Discovery News (DDN) by Andreas Persidis September 2011 After many years of talking about it, the patent cliff is finally with us in a big way. Starting with Pfizer’s Lipitor this coming November, Big Pharma is projected to lose more than $60 billion in the next five to six years from … Read More
Saving time and money The resources required to bring a new drug to market are as well-known as they are staggering: upwards of $1.3 billion in costs, 10 to 15 years from target selection to approval, and an overall failure rate approaching 95%.
Biovista’s drug safety search aids clinical outcomes. Interview to Bio-IT World By Kevin Davies June 8, 2011 | Biovista began as a hobby,” admits the company’s eloquent president, Aris Persidis. But after “dabbling” with the firm for a few years, Persidis incorporated the company in the United States in 2005. Headquartered in Charlottesville, Virginia, Biovista … Read More
CHARLOTTESVILLE, Virginia, June 3, 2011 — Biovista announced today that it is presenting at the Drug Repositioning Conference, San Francisco, on July 13 2011. Biovista’s President, Dr. Aris Persidis, will give a presentation on systematic repositioning using Mechanism of Action. The Drug Repositioning Conference is one of the prime events in this space and has been … Read More